Neurophysiological classification of the Carpal Tunnel Syndrome

The aim of this study was to evaluate the clinical correlation of the neurophysiological scale of the Carpal Tunnel Syndrome (CTS). The hands were classified in 6 grades: minimum/grade 1 (comparative test / altered short segment, normal sensitive and motor conductions), mild/grade 2 (altered sensitive conduction, normal motor conduction), moderate/grade 3 (altered sensitive and motor conductions, normal sensitive amplitude), moderate/grade 4 (altered sensitive and motor conductions, low sensitive amplitude), severe/grade 5 (absent sensitive conduction, altered motor conduction) and extremely severe/grade 6 (absent sensitive and motor conductions). A prospective study was carried out in 400 hands with CTS. 56 hands (14%) were classified as grade 1,109 hands (27.3%) as grade 2, 129 hands (32.3%) as grade 3, 78 hands (19.5%) as grade 4, 22 hands (5.5%) as grade 5 and 6 hands (1.5%) as grade 6. There was a significant positive correlation (p < 0.01) between the neurophysiological scale of CTS and the patients’ ages, the duration of CTS, the frequency of reported classical CTS history and the frequency of night pain symptoms, paresthesia and numbness. Additionally, there was a significant positive correlation between the neurophysiological scale and the frequency of Tinel`s sign, hypoesthesia on the 2nd digit, weakness and hypotrophy of the thenar muscles.O objetivo deste trabalho foi avaliar a correlação clínica da escala neurofisiológica da Síndrome do Túnel do Carpo (STC). As mãos foram classificadas em 6 graus: mínimo/grau 1 (teste comparativo/segmento curto alterado, conduções sensitiva e motora normais), leve/grau 2 (condução sensitiva alterada, condução motora normal), moderada/grau 3 (conduções sensitiva e motora alteradas, amplitude sensitiva normal), moderada/grau 4 (conduções sensitiva e motora alteradas, amplitude sensitiva baixa), grave/grau 5 (condução sensitiva ausente, condução motora alterada) e extremo/grau 6 (conduções sensitiva e motora ausentes). Foi realizado um estudo prospectivo em 400 mãos com STC. Foram classificadas 56 mãos (14,0%) como grau 1, 109 mãos (27,3%) como grau 2, 129 mãos (32,3%) como grau 3, 78 mãos (19,5%) como grau 4, 22 mãos (5,5%) como grau 5 e 6 mãos (1,5%) como grau 6. Houve uma correlação positiva significativa (p<0,01) da escala neurofisiológica da STC com a idade dos pacientes, o tempo de duração da STC, a freqüência de relato de história clássica de STC e a freqüência dos sintomas dor noturna, parestesia e dormência. Também houve uma correlação positiva significativa entre a freqüência do sinal de Tinel, hipoestesia no 2° dedo, fraqueza e hipotrofia dos músculos tenares com a escala neurofisiológica da STC

Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial

Carvalho, Lucas Pedreira de. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Pesquisa Clínica. Salvador, BA, Brasil. a Postgraduate Program in Medicine and Health, b Psychiatry Service, University Hospital, Universidade Federal da Bahia, Salvador, c LiNC—Laboratório Interdisciplinar de Neurociências Clínicas, d Depatment of Anesthesiology, e PRODAF—Programa de Transtornos Afetivos, Universidade Federal de São Paulo, São Paulo, f Postgraduate Program in Psychology, Institute of Psychology, g Immunology Service, Universidade Federal da Bahial, h Clinical Research Laboratory (LAPEC), Gonçalo Moniz Institute, Fiocruz-Bahia, Salvador, Brazil, i McGill Group for Suicide Studies, Douglas Mental Health University Institute & Department of Psychiatry, McGill University, Montreal, Canada, j Center for Research and Clinical Trials Sinapse-Bairral, Instituto Bairral de Psiquiatria, Itapira, Brazil.Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2018-12-21T16:28:46Z No. of bitstreams: 1 Melo FSC Comparative_study_of_esketamine_and_racemic.64.pdf: 212500 bytes, checksum: 350198044d38100f8cc9dd703451de7c (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2018-12-21T16:45:26Z (GMT) No. of bitstreams: 1 Melo FSC Comparative_study_of_esketamine_and_racemic.64.pdf: 212500 bytes, checksum: 350198044d38100f8cc9dd703451de7c (MD5)Made available in DSpace on 2018-12-21T16:45:26Z (GMT). No. of bitstreams: 1 Melo FSC Comparative_study_of_esketamine_and_racemic.64.pdf: 212500 bytes, checksum: 350198044d38100f8cc9dd703451de7c (MD5) Previous issue date: 2018Allergan and Lundbeck and research fees from Janssen Pharmaceutical during the last 12 months. ALTL has received consulting fees from Janssen Pharmaceutical, Daiichi Sankyo Brasil, Cristalia Produtos Químicos e Farmacêuticos, Libbs Farmacêutica and SanofiAventis and has received research fees from Eli Lilly, H. Lundbeck A/S, Servier Laboratories, Hoffman-La Roche and Forum Pharmaceuticals during the last 12 months.Múltipla - ver em NotasThe use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, the S (+) enantiomer of ketamine, is the most widely used form in the anesthetic environment in some countries, and new studies have shown that it may also be effective in depression and with better tolerability. However, no study so far has directly compared esketamine with racemic ketamine. Here we propose a protocol of a clinical trial to evaluate esketamine as a noninferior medicationMethods/design: This study protocol is for a randomized, controlled, double-blind noninferiority clinical trial. Subjects will be 18 years or older, with major depression characterized as treatment-resistant. Participants will receive a single infusion of either esketamine (0.25mg/kg) or ketamine (0.5 mg/kg) over 40 minutes. The primary outcome will be the difference in remission rates between the 2 treatment arms at 24 and 72hours after drug infusion. Secondary outcomes will include other timepoints, measurements of cognition, dissociation, and blood biomarkers. Discussion: A head-to-head study is the best way to evaluate whether the esketamine is in fact comparable to the racemic ketamine in terms of both efficacy and safety, and, if positive, it would be an initial step to increase the access to that type of treatment worldwide. Ethics and dissemination: The study was approved by the local Institutional Review Board (University Hospital Professor Edgard Santos—Federal University of Bahia—Number: 46657415.0.0000.0049). Subjects will only participate after voluntarily agreeing and signing the Informed Consent Form. The study findings will be published in peer-reviewed journals and presented at national and international conferences. Trial registration: This trial has been registered in the Japan Primary Registries Network (JPRN): UMIN000032355, which is affiliated with the World Health Organization. when compared to ketamine in the treatment of patients with treatment-resistant depression